Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Blood advances·2025
Same author

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.

Current medical research and opinion·2024
Same author

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

Blood advances·2023
Same author

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.

Cancer reports (Hoboken, N.J.)·2022

Related Experiment Video

Updated: Jun 15, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

[Malignant lymphoma: diagnosis and initial management].

Richard Delarue1

  • 1Service d'hématologie adultes, Hôpital Necker (AP-HP), 75743 Paris Cedex 15. richard.delarue@nck.aphp.fr

La Revue Du Praticien
|March 13, 2010
PubMed
Summary

Diagnosing malignant lymphoma involves identifying enlarged lymph nodes and spleen, often requiring pathological analysis. Early detection and specialized hematological care are crucial for effective treatment based on lymphoma subtype and patient factors.

Related Experiment Videos

Last Updated: Jun 15, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Oncology
  • Pathology
  • Hematology

Context:

  • Malignant lymphoma diagnosis typically relies on clinical signs like lymphadenopathy and splenomegaly, often accompanied by systemic symptoms.
  • Pathological examination of lymph node biopsies is essential for definitive diagnosis.
  • Extra-nodal lymphoma involvement can present as the sole manifestation, affecting sites such as the digestive tract, skin, and head and neck.

Purpose:

  • To outline the diagnostic criteria and common presentations of malignant lymphoma.
  • To emphasize the necessity of pathological confirmation for lymphoma diagnosis.
  • To highlight potential complications and the importance of specialized care.

Summary:

  • Malignant lymphoma diagnosis is primarily based on enlarged lymph nodes and/or spleen, with or without general symptoms.
  • Pathological analysis of lymph node biopsies is required, though extra-nodal involvement can be the unique sign.
  • Common sites include the digestive tract, skin, and head and neck, with potential complications necessitating emergency management.

Impact:

  • Accurate and timely diagnosis is critical for initiating appropriate treatment strategies.
  • Understanding lymphoma presentation aids in early detection and intervention.
  • Management requires specialized hematological expertise tailored to histological subtype, prognostic factors, and comorbidities.